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Lung hyperpermeability aﬀects the development of acute respiratory distress syndrome (ARDS),  but 
therapeutic strategies for the control of microvascular permeability have not been established.  We 
examined the eﬀects of edaravone,  dexamethasone,  and N-monomethyl-L-arginine (L-NMMA) on 
permeability changes in human pulmonary microvascular endothelial cells (PMVEC) under a hypercy-
tokinemic state.  Human PMVEC were seeded in a Boyden chamber.  After monolayer conﬂuence was 
achieved,  the culture media were replaced respectively by culture media containing edaravone,  dex-
amethasone,  and L-NMMA.  After 24-h incubation,  the monolayer was stimulated with tumor necrosis 
factor-α (TNF-α) and interleukin-1β (IL-1β).  Fluorescein-labeled dextran was added.  Then the trans-
human PMVEC leak was measured.  Expressions of vascular endothelial-cadherin (VE-cadherin) and 
zonula occludens-1 protein (ZO-1) were evaluated using real-time quantitative polymerase chain reac-
tion and immunoﬂuorescence microscopy.  The results showed that TNF-α＋IL-1β markedly increased 
pulmonary microvascular permeability.  Pretreatment with edaravone,  dexamethasone,  or L-NMMA 
attenuated the hyperpermeability and inhibited the cytokine-induced reduction of VE-cadherin expres-
sion on immunoﬂuorescence staining.  Edaravone and dexamethasone increased the expression of ZO-1 
at both the mRNA and protein levels.  Edaravone and dexamethasone inhibited the permeability 
changes of human PMVEC,  at least partly through an enhancement of VE-cadherin.  Collectively,  
these results suggest a potential therapeutic approach for intervention in patients with ARDS.
Key words: pulmonary microvascular endothelial cells,  permeability,  edaravone,  vascular endothelial-cad-
herin,  zonula occludens-1 protein
nﬂuenza virus infection causes severe pneumo-
nia,  especially in children and adults with 
underlying disease [1,  2].  Many patients need venti-
lator support because of severe complications such as 
acute respiratory distress syndrome (ARDS) [3].  
Inﬂuenza A/H1N1pandemic viruses have been reported 
to show an aﬃnity for type II alveolar epithelial cells 
and to invade the lung directly [4].  Although lung 
hyperpermeability is thought to contribute to ARDS 
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development [5],  no clinically available medication 
for the control of vascular permeability has been 
established.
　 Vascular endothelial cell-cell adhesions that control 
vascular permeability are organized mainly by adher-
ence junctions and tight junctions [6,  7].  Adherence 
junctions are formed by members of the cadherin fam-
ily.  Vascular endothelial-cadherin (VE-cadherin) receives 
positive and negative control by various signals.  It 
regulates endothelial cell adhesion and barrier func-
tion of blood vessels dynamically [6,  8].  Tight junc-
tions include transmembrane molecules such as occlu-
din,  claudin,  and junctional adhesion molecules.  
Zonula occludens-1 protein (ZO-1),  a lining protein 
of tight junctions,  connects transmembrane molecules 
with the actin cytoskeleton.
　 In response to inﬂammatory cytokines,  the vascular 
endothelium expresses cellular adhesion molecules 
including intercellular adhesion molecule 1 (ICAM-1) 
and vascular cell adhesion molecule 1 (VCAM-1),  and 
secretes chemokines such as monocyte chemoattrac-
tant protein-1 (MCP-1) and interleukin-8 (IL-8) to 
upregulate leukocyte recruitment into inﬂamed tissues 
[9].
　 Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one),  
which is used to treat cerebral infarction as a free 
radical scavenger [10],  reportedly protects various 
organs [11].  Several animal studies have demon-
strated that edaravone prevents lung injury induced by 
various factors,  including anticancer drugs,  lipopoly-
saccharide,  and acute pancreatitis via antioxidant and 
anti-inﬂammatory eﬀects [12-15].  Nevertheless,  lit-
tle is known about whether edaravone has any protec-
tive eﬀect for ARDS characterized by enhanced vas-
cular permeability.
　 The 2009 pandemic inﬂuenza A virus infection 
caused severe pneumonia and ARDS related to lung 
hyperpermeability more often than seasonal inﬂuenza 
virus infection did [2,  3].  Although we initially tried 
to perform inﬂuenza virus infection experiments using 
human pulmonary microvascular endothelial cells 
(PMVEC),  neither inﬂuenza A/H1N1pandemic nor 
A/H3N3Aichi was found to infect endothelial cells or 
change the permeability parameters (unpublished data).
　 Therefore,  we speciﬁcally examined the permea-
bility changes of endothelial cells by inﬂammatory 
cytokines that are produced during severe infectious 
diseases including inﬂuenza.  For this study,  we 
established a human PMVEC monolayer model to 
examine the barrier permeability changes that occur 
in endothelial cells in a hypercytokinemic state.  
Dexamethasone and nitric oxide synthase (NOS) 
inhibitor are reported to decrease pulmonary vascular 
hyperpermeability in ARDS [16,  17].  Therefore,  we 
examined the therapeutic eﬀects of edaravone on 
permeability changes and,  in the same experimental 
setting,  compared the eﬀects of edaravone to those of 
dexamethasone and NOS inhibitor.
Materials and Methods
　 Cell culture. Human PMVEC were purchased 
from Lonza Group,  Ltd.  (Walkersville,  MD,  USA) 
and were maintained using a BulletKit (EGM-2MV;  
Lonza) as recommended by the manufacturer.  The 
cells were cultured in 95ｵ air,  5ｵ CO2 at 37℃.  All 
experiments were performed on cells in the 3rd to 
6th passage.
　 Permeability assay. A Boyden chamber was 
used for the permeability evaluation.  Human PMVEC 
were seeded in Transwell Inserts (3.0µm pore; Becton,  
Dickinson and Co.,  Franklin Lakes,  NJ,  USA) at a 
concentration of 5×104 cells/well.  They were cul-
tured for 3 days.  After monolayer conﬂuence was 
achieved,  the culture media in the upper chamber 
(150µl) and the lower chamber (750µl) were replaced 
respectively by culture media containing edaravone 
(100µM; Mitsubishi Tanabe Pharma Corp.,  Tokyo,  
Japan),  dexamethasone (100µM; Calbiochem 
Novabiochem Corp.,  La Jolla,  CA,  USA),  and 
N-monomethyl-L-arginine (L-NMMA,  1mM;  
Calbiochem Novabiochem Corp.).  After 24h incuba-
tion,  the culture medium was replaced with culture 
medium containing each chemical and cytokines.  
Tumor necrosis factor-α (TNF-α) (Peprotech Inc.,  
Rocky Hill,  NJ,  USA) and interleukin-1β (IL-1β) 
(Peprotech Inc. ) were used as pro-inﬂammatory cytok-
ines.  In a preliminary set of experiments,  human 
PMVEC were treated with TNF-α (100ng/ml) and 
IL-1β (100ng/ml) singly or in combination.  Used 
alone,  TNF-α and IL-1β each tended to increase the 
endothelial permeability,  but the permeability changes 
were not signiﬁcant.  Only the combination of TNF-α
＋IL-1β increased the permeability signiﬁcantly 
(data not shown).  In subsequent experiments,  there-
fore,  human PMVEC were treated with TNF-α＋
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IL-1β at either of 2 concentrations (10ng/ml or 
100ng/ml) for 24h.
　 Phosphate-buﬀered saline was used as a control 
buﬀer.  To measure trans-human PMVEC dextran 
leak,  150µl assay medium containing ﬂuorescein 
isothiocyanate-labeled dextran (FITC-Dx; MW 3,000) 
(100µg/ml) was added to each upper chamber; and 
750µl assay medium was added to each lower chamber.  
After incubation for 2h at 37℃,  the ﬂuorescence 
intensity of medium from the lower chambers was 
measured at 485-538nm.  The data were expressed as 
follows: permeability index (ｵ)＝[(experimental 
clearance)－ (spontaneous clearance)]×100/[(clear-
ance of ﬁlter alone)－ (spontaneous clearance)] [18].  
The experiments were repeated 3 times,  with each 
repetition consisting of 4 replicates.
　 Lactate dehydrogenase (LDH) release assay.
Cell damage was assessed using the LDH release 
assay (LDH Cytotoxicity Detection Kit; Takara Bio 
Inc.,  Shiga,  Japan).  The percentage cytotoxicity was 
calculated as follows: cytotoxicity (ｵ)＝[experimen-
tal LDH release (OD492)－spontaneous LDH release 
(OD492)]×100/[maximum LDH release (OD492)]－
[spontaneous LDH release (OD492)].  The OD492 of 
spontaneous LDH release and the OD492 of maximum 
LDH release were obtained respectively from the 
supernatant of controls and the supernatant of the cells 
treated with 2ｵ Triton X-100.  The experiments 
were repeated twice,  with each repetition consisting 
of 4 replicates.
　 Immunofluorescence microscopy. For 
immunoﬂuorescence experiments,  the endothelial cells 
were grown on collagen I- coated slide chambers 
(Becton,  Dickinson and Co.).  They were subsequently 
treated for 24h with edaravone,  dexamethasone,  or 
L-NMMA followed by treatment with TNF-α＋  
IL-1β (10ng/ml) for 24h.  The cells were then washed 
with phosphate-buﬀered saline and ﬁxed in 2ｵ form-
aldehyde.  After permeabilization with 0.1ｵ Triton 
X-100 and blocking,  the cells were incubated with 
anti-VE-cadherin antibody (10µg/ml; R & D Systems,  
Minneapolis,  MN,  USA) and anti-ZO-1 antibody 
(5µg/ml; Genetex Inc.,  Irvine,  CA,  USA) for 60min.  
Alexa Fluor 488-conjugated antibody (Invitrogen 
Corp.,  Carlsbad,  CA,  USA) was used as a secondary 
antibody.  The nucleus was stained with 4ʼ,  6-diamid-
ino-2-phenylindole (DAPI) in mounting medium 
(Vectashield; Vector Laboratories Inc.,  Burlingame,  
CA,  USA).  Samples were evaluated under a ﬂuores-
cence microscope (BZ-9000 generation II; Keyence 
Co.,  Osaka,  Japan).  The experiments were repeated 
4 times.
　 Real-time quantitative polymerase chain reac-
tion (real-time PCR). To examine the eﬀects of 
cytokines and medications on VE-cadherin and ZO-1 
mRNA expression in human PMVEC under the 
experimental conditions employed,  real-time PCR was 
performed with total RNAs extracted from the cells 
using the speciﬁc primers presented in Table 1 [19].  
After the cells reached conﬂuence in 24-well plates,  
they were incubated for 24h with edaravone,  dexam-
ethasone,  or L-NMMA,  followed by treatment with 
TNF-α＋IL-1β.  After stimulation,  the complemen-
tary DNA was extracted using FastLane® Cell cDNA 
(Qiagen Inc.,  Hilden,  Germany).  Real-time PCR was 
performed using a real-time PCR system (7500 
Fast; Applied Biosystems,  Foster City,  CA,  USA) 
with SYBR ®Premix Ex Taq (Takara Bio Inc.).  The 
PCR mixture,  which had a total volume of 50µl,  
consisted of 1×SYBR ®Premix Ex Taq,  which 
included DNA polymerase,  SYBR Green dye,  dNTP 
mixture,  and PCR buﬀer,  0.2µM each of the forward 
and reverse primers,  and cDNA of the samples.  
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
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Table 1　 List of nucleotides used for cDNA ampliﬁcation
Target gene Sequence Length Product size
GAPDH sense GAGTCAACGGATTGGTCGT 238
antisense TTGATTTTGGAGGGATCTCG
VE-cadherin sense ACTCACCCCTTGCAATAACG 250
antisense ACAGAGCAGCCATCAGAGGT
ZO-1 sense GAACGAGGCATCATCCCTAA 218
antisense CCAGCTTCTCGAAGAACCAC
GAPDH,  glyceraldehyde 3-phosphate dehydrogenase; VE-cadherin,  vascular endothelial-cadherin; ZO-1,  zonula occludens-1 protein.
was used for normalizing the eﬃciency of cDNA syn-
thesis.  Results were based on 2 experimental condi-
tions,  each consisting of 4 replicates.
　 Enzyme-linked immunosorbent assay 
(ELISA). Expressions of adhesion molecules in the 
culture supernatant were measured following Lehleʼs 
in vitro model [20-22].  The levels of soluble ICAM-1 
(sICAM-1) and soluble VCAM-1 (sVCAM-1) were 
measured (Luminex 100/200 System; Luminex Corp.,  
Austin,  TX,  USA) with a Human CVD Panel 1 
96-well Plate Assay (Millipore Corp.,  Bedford,  MA,  
USA).  The levels of MCP-1 and IL-8 were also 
measured by ELISA (R & D Systems).  The results 
were obtained under 2 experimental conditions,  each 
consisting of 4 replicates.
　 Statistical analyses. All values were expressed 
as the mean ± SD.  Diﬀerences between groups were 
examined for statistical signiﬁcance using one-way 
analysis of variance with Tukeyʼs multiple comparison 
test.  Statistical signiﬁcance was inferred for P-values 
less than 0.05.
Results
　 Permeability change of the human PMVEC 
monolayer. As presented in Fig.  1,  the endothe-
lial permeability was increased signiﬁcantly by 
TNF-α＋IL-1β at the concentrations of 10ng/ml 
and 100ng/ml compared to the control group.  No 
signiﬁcant diﬀerence was found between 10ng/ml and 
100ng/ml.  For subsequent experiments,  the concen-
tration of 10ng/ml was adopted.  Pretreatment with 
edaravone (100µM) signiﬁcantly decreased the perme-
ability by 45ｵ compared with the group treated with 
TNF-α＋IL-1β alone (Fig.  2A).  Pretreatment with 
dexamethasone (100µM) signiﬁcantly decreased the 
permeability by 35ｵ compared with the group treated 
with TNF-α＋IL-1β alone (Fig.  2B).  Pretreatment 
with L-NMMA (1mM) signiﬁcantly decreased the 
permeability by 50ｵ compared with the group exposed 
to only TNF-α＋IL-1β (Fig.  2C).
　 Cell cytotoxicity. Cell damage was assessed by 
using an LDH release assay.  The LDH release was 
not altered signiﬁcantly by the pretreatment of 
endothelial cells with edaravone,  dexamethasone,  or 
L-NMMA compared with TNF-α＋IL-1β alone 
(Fig.  3).  This result showed that the attenuation of 
hyperpermeability by pretreatment in this study was 
not caused by the inhibition of cell membrane damage 
or cell death.
　 Eﬀ ects of edaravone, dexamethasone, and 
L-NMMA on the expression of endothelial 
adherence junction protein VE-cadherin. The 
eﬀects of edaravone,  dexamethasone,  and L-NMMA 
on the expression of VE-cadherin were examined to 
identify the relation between permeability changes and 
cell-cell adhesion.  Immunofluorescence staining 
showed that staining for VE-cadherin was reduced 
after TNF-α＋IL-1β stimulation.  Pretreatment with 
edaravone,  dexamethasone,  or L-NMMA for 24h 
attenuated the eﬀects of TNF-α＋IL-1β stimulation 
(Figs.  4A-4E).  Pretreatment with edaravone,  dex-
amethasone,  or L-NMMA for 24h followed by treat-
ment with TNF-α＋IL-1β for 3h did not alter the 
mRNA level of VE-cadherin (Fig.  4F).
　 Eﬀ ects of edaravone, dexamethasone, and 
L-NMMA on the expression of endothelial tight 
junction protein ZO-1. No change of ZO-1 was 
shown by treatment with TNF-α＋IL-1β for 24h.  
The near-circumferential expression of ZO-1 was 
increased by pretreatment with edaravone or dexam-
ethasone for 24h compared with the other groups 
(Figs.  5A-5E).  In human PMVEC,  ZO-1 mRNA 
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Fig. 1　 Dose response of the permeability change in human pul-
monary microvascular endothelial cells (PMVEC) stimulated with 
TNF-α＋ IL-1β for 24h.  Either concentration at 10ng/ml or 
100ng/ml in each increased the permeability signiﬁcantly.  No sig-
niﬁcant diﬀerence was found between 10ng/ml and 100ng/ml.  
Data are presented as mean ± SD (n＝4 in each group).  ＊p＜
0.05 in comparison with PBS group.  TNF-α,  tumor necrosis fac-
tor-α; IL-1β,  interleukin-1β; PBS,  phosphate-buﬀered saline.
expression was unaﬀected by stimulation with TNF-α
＋IL-1β,  but it was increased signiﬁcantly by pre-
treatment with edaravone or dexamethasone (Fig.  5F).
　 Eﬀ ects of TNF-α＋IL-1β, edaravone, dex-
amethasone, and L-NMMA on the generation of 
sICAM-1, sVCAM-1, MCP-1, and IL-8 in 
human PMVEC. Leukocyte recruitment into 
inﬂamed tissues engenders microvascular hyperperme-
ability.  Therefore,  the eﬀects of TNF-α＋IL-1β,  
edaravone,  dexamethasone,  and L-NMMA on the 
production of sICAM-1,  sVCAM-1,  MCP-1,  and 
IL-8 in human PMVEC were examined.
　 Treatment of human PMVEC with TNF-α＋  
IL-1β for longer than 6h caused a signiﬁcant increase 
in the production of sICAM-1 and sVCAM-1 in the 
supernatant compared with the non-stimulated cells.  
The levels of MCP-1 and IL-8 were increased sig-
niﬁcantly after 3h and 6h,  respectively,  by the 
administration of TNF-α＋IL-1β (Fig.  6).
　 We examined the inhibitory eﬀects of pretreatment 
with edaravone,  dexamethasone,  and L-NMMA for 
24h on the production of adherence molecules and 
chemokines.  The sICAM-1 and sVCAM-1 production 
tended to be decreased by these pretreatments,  but 
the diﬀerences were not signiﬁcant.  Pretreatment 
with dexamethasone signiﬁcantly inhibited the produc-
tion of MCP-1 and IL-8 induced by TNF-α＋IL-1β 
(Fig.  7).
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Fig. 3　 Effects of edaravone,  dexamethasone,  and 
N-monomethyl-L-arginine (L-NMMA) on cell cytotoxicity in human 
PMVEC stimulated with TNF-α＋ IL-1β.  In evaluation of cell 
cytotoxicity as determined by the LDH release,  no signiﬁcant diﬀer-
ences were found among groups.
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Fig. 2　 Eﬀects of pretreatment for 24h with edaravone (A),  
dexamethasone (B),  and N-monomethyl-L-arginine (L-NMMA) (C) 
on the permeability changes in human PMVEC stimulated with 
TNF-α＋ IL-1β for 24h.  Each chemical signiﬁcantly suppressed 
the hyperpermeability because of TNF-α＋ IL-1β.  Although the 
diﬀerence was not signiﬁcant,  each chemical showed a tendency 
to decrease permeability compared with control by itself.  Data are 
presented as mean ± SD (n＝4 in each group).  ＊p＜0.05,  ＊＊p＜
0.01.
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Fig. 4　 Eﬀects of TNF-α＋ IL-1β,  edaravone,  dexamethasone,  and N-monomethyl-L-arginine (L-NMMA) on the expression of vascular 
endothelial (VE)-cadherin in human PMVEC.  For immunoﬂuorescence analysis,  human PMVEC were treated with culture medium alone 
(A),  with TNF-α＋ IL-1β for 24h (B),  pretreatment with edaravone (C),  with dexamethasone (D),  with L-NMMA (E) for 24h and treat-
ment with TNF-α＋ IL-1β for 24h.  TNF-α＋ IL-1β reduced staining for VE-cadherin.  Pretreatment with edaravone,  dexamethasone,  or 
L-NMMA apparently inhibited this eﬀect.  VE-cadherin mRNA (F) was not altered signiﬁcantly by these chemicals.  Representative immuno-
ﬂuorescence studies are shown.
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Fig. 5　 Eﬀects of TNF-α＋ IL-1β,  edaravone,  dexamethasone,  and N-monomethyl-L-arginine (L-NMMA) on the expression of zonula 
occuldens-1 protein (ZO-1) in human PMVEC.  For immunoﬂuorescence analysis,  human PMVEC were treated with culture medium alone 
(A),  with TNF-α＋ IL-1β for 24h (B),  pretreatment with edaravone (C),  with dexamethasone (D),  with L-NMMA (E) for 24h and treat-
ment with TNF-α＋ IL-1β for 24h.  No change of ZO-1 expression was found from TNF-α＋ IL-1β treatment.  Pretreatment with edara-
vone or dexamethasone increased ZO-1 expression compared with control or cytokine group.  Representative immunoﬂuorescence studies 
are shown.  ZO-1 mRNA (F) was enhanced by pretreatment with edaravone or dexamethasone compared with control and 
TNF-α＋ IL-1β group.  Data are presented as mean ± SD (n＝4 in each group).  ＊p＜0.05 in comparison with TNF-α＋ IL-1β group.  
＊＊p＜0.01 in comparison with TNF-α＋ IL-1β group.
Discussion
　 Various diseases including viral pneumonia,  sepsis,  
and acute pancreatitis can cause ARDS,  a state of 
pulmonary edema caused by the inﬂux of protein-rich 
edema ﬂuid into the air spaces.  ARDS can also occur 
as a consequence of endothelial and epithelial injury 
[5].  Microvascular endothelial cells respond to local 
changes in biological needs caused by inﬂammation.  
These cells play an important role in the control of 
exchange of leukocytes and ﬂuids between the lung 
microvessels and alveoli [23,  24].
　 The cytokine proﬁles of suctioned pulmonary 
secretions from children infected with inﬂuenza 
A/H1N1pdm revealed that TNF-α,  IL-1β and other 
inﬂammatory cytokine concentrations were markedly 
higher on the ﬁfth day after hospitalization than on the 
ﬁrst day [25].  It has been reported that inﬂuenza 
A/H1N1pdm viruses replicate eﬃciently in the lungs 
of infected mice,  ferrets,  and non-human primates.  
These viruses can cause remarkable pathology in the 
lungs [4].  Consequently,  locally released inﬂamma-
tory cytokines in the lung are increased in inﬂuenza 
A/H1N1pdm pneumonia,  and are likely to contribute 
to lung microvascular hyperpermeability.
　 Our experiments showed that stimulation with 
inﬂammatory cytokines (TNF-α＋IL-1β,  10ng/ml in 
each) for 24h signiﬁcantly increased dextran leakage 
across human PMVEC.  Pretreatment with edaravone,  
dexamethasone,  or L-NMMA signiﬁcantly inhibited 
the increase of permeability caused by these cytokines 
in the endothelial cells to the same extent.  Stimulation 
with inﬂammatory cytokines caused perturbation of 
VE-cadherin,  a major component of the adherence 
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Fig. 6　 Eﬀects of TNF-α＋ IL-1β on the secretion of sICAM-1,  sVCAM-1,  MCP-1,  and IL-8 in human PMVEC.  Treatment with TNF-
α＋ IL-1β (10ng/ml) for 6h signiﬁcantly increased the secretion of sICAM-1 (A),  sVCAM-1 (B),  and IL-8 (D).  The secretion of MCP-1 
(C) was increased by stimulation for 3h.  Data are presented as mean ± SD (n＝4 in each group).  ＊p＜0.05 in comparison with 0h in 
each group.  sICAM-1,  soluble intercellular adhesion molecule-1; sVCAM-1,  soluble vascular cell adhesion molecule-1;  
MCP-1,  monocyte chemoattractant protein-1; IL-8,  interleukin-8.
junction [8].  The ﬁnding that pretreatment with 
edaravone,  dexamethasone,  or L-NMMA inhibited the 
cytokine-induced perturbation of VE-cadherin sug-
gests that these medications have the eﬀect of holding 
VE-cadherin.  Diﬀerential results were observed in 
terms of the protein levels and mRNA expression of 
VE-cadherin: although no remarkable change of the 
mRNA expression was observed,  stimulation with 
inﬂammatory cytokines led to a decrease in 
VE-cadherin protein.  Pretreatment with edaravone,  
dexamethasone,  or L-NMMA inhibited the eﬀect.  
This discrepancy points to indirect eﬀects on 
VE-cadherin expression rather than to direct tran-
scriptional regulation of the VE-cadherin gene.  The 
results also showed that ZO-1 mRNA and near-cir-
cumferential expression were increased by pretreat-
ment with edaravone or dexamethasone.  These results 
support the contention that edaravone and dexametha-
sone can reinforce a tight junction through the 
enhancement of ZO-1 expression [26,  27].  
Pretreatment with edaravone or dexamethasone might 
contribute to enhancement of the tight junction,  
resulting in the inhibition of hyperpermeability in 
human PMVEC.  
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Fig. 7　 Eﬀects of edaravone,  dexamethasone,  and N-monomethyl-L-arginine (L-NMMA) on the secretion of sICAM-1,  sVCAM-1,  
MCP-1,  and IL-8 in the human PMVEC stimulated with TNF-α＋ IL-1β (10ng/ml in both).  Up-regulation of sICAM-1 and sVCAM-1 were 
not suppressed by these chemicals.  MCP-1 and IL-8 were suppressed signiﬁcantly by pretreatment with dexamethasone.  Data are pre-
sented as mean ± SD (n＝4 in each group).  ＊p＜0.05,  ＊＊p＜0.01.  sICAM-1,  soluble intercellular adhesion molecule-1;  
sVCAM-1,  soluble vascular cell adhesion molecule-1; MCP-1,  monocyte chemoattractant protein-1; IL-8,  interleukin-8.
　 Several previous studies have revealed that edara-
vone increases transmonolayer electrical resistance by 
enhancing the expression of the adherence junction 
protein [28].  Edaravone prevents the increase of 
permeability under oxidative stress [29] in human 
umbilical vein endothelial cells.  Dexamethasone 
increases VE-cadherin protein levels and rearranges 
the cytoskeleton [30].  The present study provided 
similar results that edaravone and dexamethasone 
prevented hyperpermeability in human PMVEC under 
cytokine stimulation.
　 Our experiments also showed that stimulation with 
cytokines increased the mRNA expression and protein 
levels of ICAM-1,  VCAM-1,  MCP-1,  and IL-8,  
similar to human dermal microvascular endothelial 
cells [31,  32].  Pretreatment with edaravone or dex-
amethasone showed a tendency to inhibit the expres-
sion of ICAM-1 and VCAM-1,  although the eﬀect was 
not signiﬁcant.  Pretreatment with dexamethasone 
reduced MCP-1 and IL-8 signiﬁcantly.  These results 
present the possibility that edaravone and dexametha-
sone prevent the increase of vascular permeability 
partly through the inhibition of leukocyte recruitment 
into inﬂamed tissues.
　 Our recent report described that administration of 
TNF-α enhances the expression of MMP-9,  which 
dissolves type IV collagen in the brain endothelial 
cells of mice,  and results in disorders of the blood-
brain barrier [33].  However,  administration of 
TNF-α＋IL-1β induced neither mRNA expression 
nor secretion of MMP-9 in human PMVEC (data not 
shown).  This discrepancy might have resulted from 
diﬀerences in the species,  cell types,  experimental 
conditions,  or sensitivity of detection methods.
　 In conclusion,  our experiments show that edara-
vone and dexamethasone can prevent hyperpermeabil-
ity in human PMVEC stimulated by inﬂammatory 
cytokines,  possibly through enhancement of the adher-
ence junction,  and potentially through other mecha-
nisms as well (Fig.  8).  These results might provide 
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Fig. 8　 Schematic diagram showing TNF-α＋ IL-1β -induced lung hyperpermeability and the inhibitory eﬀects of edaravone and dexam-
ethasone.
cellular- and molecular-level insight into treatment 
strategies for patients with ARDS and highly patho-
genic avian inﬂuenza pneumonia,  which strongly 
impair lung function.  Edaravone and dexamethasone 
showed the eﬀect to the same extent.  In addition,  
because edaravone has fewer side eﬀects than dexam-
ethasone [11],  edaravone alone or in combination 
with dexamethasone is expected to be eﬀective for 
therapy for ARDS in a clinical setting.
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